Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.
Amneal missed analysts’ revenue expectations by 3.4% last quarter, reporting revenues of $695.4 million, up 5.5% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Is Amneal a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Amneal’s revenue to grow 5.8% year on year to $742.8 million, slowing from the 17.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amneal has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Amneal’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts’ expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%.
Read our full analysis of Bristol-Myers Squibb’s results here and Merck’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Amneal is down 5.1% during the same time and is heading into earnings with an average analyst price target of $11.75 (compared to the current share price of $7.98).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.